Hervás I, Bello P, Falgas M, Del Olmo M I, Torres I, Olivas C, Vera V, Oliván P, Yepes A M
Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España.
Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España.
Rev Esp Med Nucl Imagen Mol. 2017 Mar-Apr;36(2):91-98. doi: 10.1016/j.remn.2016.10.003. Epub 2016 Nov 23.
Therapy with radiolabelled somatostatin analogue peptides is a promising new therapy to treat neuroendocrine tumours. The aim of this preliminary study is to present our experience with Lu-DOTATATE therapy, and evaluate tolerability and short-term efficacy in patients with tumours expressing somatostatin receptors. A total of 7 patients with metastatic neuroendocrine tumours were treated, each with 4 doses of Lu-DOTATATE. The treatment response was evaluated in the form of biochemical response (tumour markers), imaging methods (somatostatin receptor scintigraphy, computed tomography, and magnetic resonance), and functional and quality of life responses using the Karnofsky performance status scale. Treatment toxicity was also evaluated. The results obtained were as follows: Biochemical response: 60% of patients showed tumour marker levels returning to normal, while they decreased significantly in the remaining 40%. Imaging response: 85.7% had a partial response, while 14.3% showed stable disease. All (100%) patients showed a significant improvement in quality of life, with increased Karnofsky scale scores. No patient had acute or chronic toxicity, and subacute transient haematological toxicity was observed in 42.8% of patients. Despite being a preliminary study, it was found that treatment with Lu-DOTATATE is a safe treatment with few side effects, and an objective response was achieved in most patients.
用放射性标记的生长抑素类似物肽进行治疗是一种有前景的治疗神经内分泌肿瘤的新方法。这项初步研究的目的是介绍我们使用镥-奥曲肽治疗的经验,并评估生长抑素受体表达阳性患者的耐受性和短期疗效。共有7例转移性神经内分泌肿瘤患者接受治疗,每人接受4剂镥-奥曲肽。治疗反应通过生化反应(肿瘤标志物)、影像学方法(生长抑素受体闪烁显像、计算机断层扫描和磁共振成像)以及使用卡诺夫斯基功能状态量表评估功能和生活质量反应来进行评估。还对治疗毒性进行了评估。获得的结果如下:生化反应:60%的患者肿瘤标志物水平恢复正常,其余40%患者的肿瘤标志物水平显著下降。影像学反应:85.7%患者有部分反应,14.3%患者病情稳定。所有(100%)患者生活质量均有显著改善,卡诺夫斯基量表评分增加。无患者出现急性或慢性毒性,42.8%的患者观察到亚急性短暂血液学毒性。尽管这是一项初步研究,但发现镥-奥曲肽治疗是一种安全、副作用少的治疗方法,大多数患者都取得了客观反应。